Mcl-1 was upregulated after bortezomib exposure in all neuroblastoma cell lines whereas no change was identified in Bcl2, XIAP, survivin and Bcl-xl expression after bortezomib treatment (figure 5). The gene discussed is BIRC5; the disease is neuroblastoma.